Categories: DrugHealthTech
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Investors 3
Mentions in press and media 5
| Date | Title | Description |
| 28.07.2026 | Diamond Therapeutics Appoints Dr. Miri Halperin Wernli to its Board of Directors | Dr. Miri Halperin Wernli
Global healthcare exec & neuroscientist brings 30+ years leadership in biopharma innovation, neuropsychiatry & advancing science into transformative medicines
I look forward to helping Diamond translate exce... |
| 11.05.2026 | Diamond Therapeutics Receives Multi-Million Dollar US Government Funding for Phase 2 Clinical Trial of Anxiety Treatment | Diamond Therapeutics - ARPA-H Funding Graphic
ARPA-H funding will enable study’s expansion to US as part of Agency’s program to drive development of new, effective therapies for behavioral health
ARPA-H funding will accelerate our efforts t... |
| 20.04.2026 | Diamond Therapeutics Welcomes White House Executive Order on Research into Psychedelics for Mental Health Treatment | Company now conducting Phase 2 clinical trial using low doses of psilocybin for treatment of generalized anxiety disorder
The recognition that new, science-based approaches are needed is timely. The Executive Order represents important prog... |
| 29.03.2022 | Women and money making: What’s your business model? | What do women around the world think is the most important component to their personal business model? |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021.
This event will con... |
Reviews 0
